Cassava Sciences, Inc. (SAVA)
NASDAQ: SAVA · Real-Time Price · USD
3.190
-0.130 (-3.92%)
At close: Dec 5, 2025, 4:00 PM EST
3.180
-0.010 (-0.31%)
After-hours: Dec 5, 2025, 7:59 PM EST
Cassava Sciences Employees
Cassava Sciences had 30 employees as of December 31, 2024. The number of employees increased by 1 or 3.45% compared to the previous year.
Employees
30
Change (1Y)
1
Growth (1Y)
3.45%
Revenue / Employee
n/a
Profits / Employee
-$3,534,367
Market Cap
154.10M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
SAVA News
- 6 weeks ago - Halper Sadeh LLC Encourages Cassava Sciences, Inc. Shareholders to Contact the Firm to Discuss Their Rights - Business Wire
- 6 weeks ago - Cassava Sciences Appoints Dawn C. Bir to the Board of Directors - GlobeNewsWire
- 4 months ago - Cassava Reports Q2 2025 Financials Results and Provides Business Update - GlobeNewsWire
- 4 months ago - Cassava Sciences Appoints Dr. Joseph Hulihan as Chief Medical Officer - GlobeNewsWire
- 4 months ago - Cassava Sciences Reports Positive Preclinical Study Evaluating Simufilam for TSC-Related Epilepsy - GlobeNewsWire
- 5 months ago - Cassava Presents Promising Preclinical Simufilam Data at TSC Alliance Meeting - GlobeNewsWire
- 7 months ago - Cassava Appoints Angélique Bordey, PhD, to Enhance Preclinical Program in TSC - GlobeNewsWire
- 8 months ago - Cassava Announces Retirement of Chief Medical Officer, Dr. Jim Kupiec, and Appointment of Dr. Jack Moore as Senior Vice President, Clinical Development - GlobeNewsWire